Serveur d'exploration sur le lymphœdème - Analysis (UK)

Index « Auteurs » - entrée « Mark J. Taylor »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Mark J. Kransdorf < Mark J. Taylor < Mark K. Bennett  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 17.
Ident.Authors (with country if any)Title
000112 (2016) Raman Sharma [Royaume-Uni] ; Ghaith Al Jayoussi [Royaume-Uni] ; Hayley E. Tyrer [Royaume-Uni] ; Joanne Gamble [Royaume-Uni] ; Laura Hayward [Royaume-Uni] ; Ana F. Guimaraes [Royaume-Uni] ; Jill Davies [Royaume-Uni] ; David Waterhouse [Royaume-Uni] ; Darren A. N. Cook [Royaume-Uni] ; Laura J. Myhill [Royaume-Uni] ; Rachel H. Clare [Royaume-Uni] ; Andrew Cassidy [Royaume-Uni] ; Andrew Steven [Royaume-Uni] ; Kelly L. Johnston [Royaume-Uni] ; Louise Ford [Royaume-Uni] ; Joseph D. Turner [Royaume-Uni] ; Stephen A. Ward [Royaume-Uni] ; Mark J. Taylor [Royaume-Uni]Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis
000231 (2015) Rachel H. Clare [Royaume-Uni] ; Darren A N. Cook [Royaume-Uni] ; Kelly L. Johnston [Royaume-Uni] ; Louise Ford [Royaume-Uni] ; Stephen A. Ward [Royaume-Uni] ; Mark J. Taylor [Royaume-Uni]Development and validation of a high-throughput anti-Wolbachia whole-cell screen: a route to macrofilaricidal drugs against onchocerciasis and lymphatic filariasis.
000268 (2014) Martin Walker [Royaume-Uni] ; Sabine Specht [Allemagne] ; Thomas S. Churcher [Royaume-Uni] ; Achim Hoerauf [Allemagne] ; Mark J. Taylor [Royaume-Uni] ; María-Gloria Basá Ez [Royaume-Uni]Therapeutic Efficacy and Macrofilaricidal Activity of Doxycycline for the Treatment of River Blindness
000296 (2014) Kelly L. Johnston [Royaume-Uni] ; Louise Ford ; Mark J. TaylorOvercoming the challenges of drug discovery for neglected tropical diseases: the A·WOL experience.
000347 (2014) Alice Halliday [Royaume-Uni] ; Ana F. Guimaraes [Royaume-Uni] ; Hayley E. Tyrer [Royaume-Uni] ; Haelly Mejane Metuge [Cameroun] ; Chounna Ndongmo Winston Patrick [Cameroun] ; Kengne-Ouafo Jonas Arnaud [Cameroun] ; Tayong Dizzle Bita Kwenti [Cameroun] ; George Forsbrook [Royaume-Uni] ; Andrew Steven [Royaume-Uni] ; Darren Cook [Royaume-Uni] ; Peter Enyong [Cameroun] ; Samuel Wanji [Cameroun] ; Mark J. Taylor [Royaume-Uni] ; Joseph D. Turner [Royaume-Uni]A murine macrofilaricide pre-clinical screening model for onchocerciasis and lymphatic filariasis
000418 (2013) Mark J. Taylor [Royaume-Uni] ; Achim Hoerauf [Allemagne] ; Simon Townson [Royaume-Uni] ; Barton E. Slatko [États-Unis] ; Stephen A. Ward [Royaume-Uni]Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis
000536 (2012) Frédéric Landmann [États-Unis] ; Odile Bain [France] ; Coralie Martin [France] ; Shigehiko Uni [Malaisie] ; Mark J. Taylor [Royaume-Uni] ; William Sullivan [États-Unis]Both asymmetric mitotic segregation and cell-to-cell invasion are required for stable germline transmission of Wolbachia in filarial nematodes
000720 (2010) Mark J. Taylor [Royaume-Uni] ; Achim Hoerauf ; Moses BockarieLymphatic filariasis and onchocerciasis.
000723 (2010) Kelly L. Johnston [Royaume-Uni] ; Bo Wu [États-Unis] ; Ana Guimarães [Royaume-Uni] ; Louise Ford [Royaume-Uni] ; Barton E. Slatko [États-Unis] ; Mark J. Taylor [Royaume-Uni]Lipoprotein biosynthesis as a target for anti-Wolbachia treatment of filarial nematodes
000831 (2009) Moses J. Bockarie [Royaume-Uni] ; Mark J. Taylor ; John O. GyapongCurrent practices in the management of lymphatic filariasis.
000A75 (2006) Joseph D. Turner [Royaume-Uni] ; Sabine Mand [Allemagne] ; Alexander Yaw Debrah [Ghana] ; Johannes Muehlfeld [Allemagne] ; Kenneth Pfarr [Allemagne] ; Helen F. Mcgarry [Royaume-Uni] ; Ohene Adjei [Ghana] ; Mark J. Taylor [Royaume-Uni] ; Achim Hoerauf [Allemagne]A Randomized, Double-Blind Clinical Trial of a 3-Week Course of Doxycycline plus Albendazole and Ivermectin for the Treatment of Wuchereria bancrofti Infection
000C48 (2003) Mark J. Taylor [Royaume-Uni]Wolbachia in the inflammatory pathogenesis of human filariasis.
000C52 (2003) William H. Makunde [Tanzanie] ; Leo M. Kamugisha [Tanzanie] ; Julius J. Massaga [Tanzanie] ; Rachel W. Makunde [Tanzanie] ; Zakana X. Savael [Tanzanie] ; Juma Akida [Tanzanie] ; Fred M. Salum [Tanzanie] ; Mark J. Taylor [Royaume-Uni]Treatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasis
000C63 (2003) David H. Molyneux [Royaume-Uni] ; Mark Bradley ; Achim Hoerauf ; Dominique Kyelem ; Mark J. TaylorMass drug treatment for lymphatic filariasis and onchocerciasis.
000E76 (2000) Mark J. Taylor [Royaume-Uni] ; Helen F. Cross [Royaume-Uni] ; Katja Bilo [Royaume-Uni]Inflammatory Responses Induced by the Filarial Nematode Brugia malayi Are Mediated by Lipopolysaccharide-like Activity from Endosymbiotic Wolbachia Bacteria
001122 (1997) Mark J. Taylor [Royaume-Uni] ; Katja Bilo [Royaume-Uni]Pro-inflammatory responses induced by lymphatic filarial parasites
001886 (????) Mark J. Taylor [Royaume-Uni] ; Williams H. Makunde ; Helen F. Mcgarry ; Joseph D. Turner ; Sabine Mand ; Achim HoeraufMacrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial.

List of associated KwdEn.i

Nombre de
documents
Descripteur
8Animals
8Elephantiasis, Filarial (drug therapy)
8Humans
7Wolbachia (drug effects)
6Onchocerciasis (drug therapy)
4Elephantiasis, Filarial (parasitology)
4Elephantiasis, Filarial (prevention & control)
3Anti-Bacterial Agents (therapeutic use)
3Female
3Filaricides (pharmacology)
3Filaricides (therapeutic use)
3Male
2Albendazole (therapeutic use)
2Anti-Bacterial Agents (pharmacology)
2Antinematodal Agents (therapeutic use)
2Brugia malayi (drug effects)
2Dose-Response Relationship, Drug
2Doxycycline (therapeutic use)
2Drug Discovery
2Elephantiasis, Filarial (diagnosis)
2Elephantiasis, Filarial (physiopathology)
2Elephantiasis, Filarial (transmission)
2Ivermectin (pharmacology)
2Ivermectin (therapeutic use)
2Mice
2Mice, Inbred BALB C
2Mice, SCID
2Neglected Diseases (drug therapy)
2Onchocerciasis (diagnosis)
2Onchocerciasis (physiopathology)
2Onchocerciasis (prevention & control)
2Wuchereria bancrofti (drug effects)
2Wuchereria bancrofti (microbiology)
1Adolescent
1Adult
1Africa
1Africa South of the Sahara
1Age Factors
1Aged
1Albendazole (pharmacology)
1Anti-Bacterial Agents (administration & dosage)
1Anti-Bacterial Agents (pharmacokinetics)
1Antinematodal Agents (pharmacology)
1Blindness (parasitology)
1Brugia (drug effects)
1Brugia (microbiology)
1Brugia malayi
1Brugia malayi (microbiology)
1Brugia malayi (parasitology)
1Brugia malayi (physiology)
1Cell Line
1Child
1Culex (parasitology)
1Culicidae
1Delivery of Health Care
1Dermatitis (parasitology)
1Dermatologic Agents (therapeutic use)
1Diethylcarbamazine (therapeutic use)
1Disease Models, Animal
1Double-Blind Method
1Doxycycline (administration & dosage)
1Doxycycline (pharmacokinetics)
1Doxycycline (pharmacology)
1Drug Discovery (methods)
1Drug Discovery (standards)
1Drug Evaluation, Preclinical
1Drug Resistance
1Drug Therapy, Combination
1Elephantiasis, Filarial (complications)
1Elephantiasis, Filarial (epidemiology)
1Elephantiasis, Filarial (pathology)
1Endemic Diseases (prevention & control)
1Gerbillinae
1Global Health
1Gram-Negative Bacterial Infections (complications)
1Granuloma (parasitology)
1High-Throughput Screening Assays (methods)
1High-Throughput Screening Assays (standards)
1India
1Inflammation
1Insect Vectors (parasitology)
1Loiasis (drug therapy)
1Loiasis (parasitology)
1Lymphadenitis (parasitology)
1Lymphangitis (parasitology)
1Lymphedema (parasitology)
1Macrolides (therapeutic use)
1Menotropins
1Microfilariae (drug effects)
1Middle Aged
1Minocycline (administration & dosage)
1Minocycline (pharmacokinetics)
1Neglected Diseases (diagnosis)
1Neglected Diseases (prevention & control)
1Onchocerca
1Onchocerca (microbiology)
1Onchocerca volvulus (drug effects)
1Onchocerca volvulus (microbiology)
1Onchocerca volvulus (physiology)
1Onchocerciasis (complications)

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/UK/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i -k "Mark J. Taylor" 
HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i  \
                -Sk "Mark J. Taylor" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/UK/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    UK
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Mark J. Taylor
}}

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024